Press Releases :: Sutro Biopharma, Inc. (STRO)

Mar 18, 2021 7:00 am EDT

Sutro Biopharma Reports Full Year 2020 Financial Results and Provides Business Highlights and 2021 Anticipated Milestones

Feb 23, 2021 7:00 am EST

Sutro Biopharma to Participate in the Cowen 41st Annual Healthcare Conference

Jan 21, 2021 7:00 am EST

Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer

Jan 5, 2021 7:00 am EST

Sutro Biopharma to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference

Dec 11, 2020 4:01 pm EST

Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Dec 8, 2020 9:10 pm EST

Sutro Biopharma Announces Pricing of $126.0 Million Public Offering

Dec 7, 2020 4:00 pm EST

Sutro Biopharma Announces Proposed Public Offering of 5 Million Shares of Common Stock

Dec 7, 2020 10:00 am EST

Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting

Dec 3, 2020 4:30 pm EST

Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer

Dec 1, 2020 7:00 am EST

Sutro Biopharma Announces Appointment of Jon M. Wigginton, M.D., to Board of Directors